Earlier on Wednesday, MannKind reported Q1 revenue $ $66.3M, consensus $60.5M .”We achieved our eighth consecutive quarter of revenue growth putting us on a run rate of over $250 million in revenue for 2024,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “In the last week, we received Fast Track designation and clearance of the IND for MNKD-101 which may allow us to bring this innovative product to patients more quickly.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
- MannKind: FDA grants Fast Track designation of Clofazimine Inhalation Suspension
- Is MNKD a Buy, Before Earnings?
- MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
- MannKind to proceed with Phase 1 Nintedanib Dpi (Mnkd-201) study